Načítá se...
Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy
OBJECTIVE: Assessment of 12-month safety of ospemifene 60 mg/day for treatment of postmenopausal women with vulvar and vaginal atrophy (VVA). METHODS: In this 52-week, randomized, double-blind, placebo-controlled, parallel-group study, women 40–80 years with VVA and an intact uterus were randomized...
Uloženo v:
| Hlavní autoři: | , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Informa Healthcare
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3971738/ https://ncbi.nlm.nih.gov/pubmed/23984673 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/13697137.2013.834493 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|